This article first appeared on GuruFocus.

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $61.88 million, and the earnings are expected to come in at $0.84 per share. The full year 2025's revenue is expected to be $281.09 million and the earnings are expected to be $5.46 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Signs with RIGL.

Is RIGL fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Rigel Pharmaceuticals Inc (NASDAQ:RIGL) have increased from $247.64 million to $281.10 million for the full year 2025. For 2026, revenue estimates have risen from $233.21 million to $277.01 million. Similarly, earnings estimates have increased from $3.76 per share to $5.46 per share for the full year 2025, and from $1.59 per share to $3.52 per share for 2026.

In the previous quarter ending on 2025-06-30, Rigel Pharmaceuticals Inc's (NASDAQ:RIGL) actual revenue was $101.69 million, which beat analysts' revenue expectations of $88.95 million by 14.32%. Rigel Pharmaceuticals Inc's (NASDAQ:RIGL) actual earnings were $3.28 per share, which surpassed analysts' earnings expectations of $2.58 per share by 27.13%. After releasing the results, Rigel Pharmaceuticals Inc (NASDAQ:RIGL) was up by 22.98% in one day.

Based on the one-year price targets offered by 6 analysts, the average target price for Rigel Pharmaceuticals Inc (NASDAQ:RIGL) is $38.33, with a high estimate of $67.00 and a low estimate of $23.00. The average target implies an upside of 21.38% from the current price of $31.58.

Based on GuruFocus estimates, the estimated GF Value for Rigel Pharmaceuticals Inc (NASDAQ:RIGL) in one year is $27.02, suggesting a downside of -14.44% from the current price of $31.58.

Based on the consensus recommendation from 6 brokerage firms, Rigel Pharmaceuticals Inc's (NASDAQ:RIGL) average brokerage recommendation is currently 2.5, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.